Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H11N7 |
Molecular Weight | 253.2626 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(N=C(C3=CC=CC=C3)C(N)=N2)C(N)=N1
InChI
InChIKey=FNYLWPVRPXGIIP-UHFFFAOYSA-N
InChI=1S/C12H11N7/c13-9-7(6-4-2-1-3-5-6)16-8-10(14)18-12(15)19-11(8)17-9/h1-5H,(H6,13,14,15,17,18,19)
DescriptionSources: http://www.drugbank.ca/drugs/DB00384Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/triamterene.html
Sources: http://www.drugbank.ca/drugs/DB00384
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/triamterene.html
Triamterene, a relatively weak, potassium-sparing diuretic and antihypertensive, is used in the management of hypokalemia. Triamterene inhibits the epithelial sodium channels on principal cells in the late distal convoluted tubule and collecting tubule, which are responsible for 1-2% of total sodium reabsorption. As sodium reabsorption is inhibited, this increases the osmolarity in the nephron lumen and decreases the osmolarity of the interstitium. Since sodium concentration is the main driving force for water reabsorption, triamterene can achieve a modest amount of diuresis by decreasing the osmotic gradient necessary for water reabsorption from lumen to interstitium. Triamterene also has a potassium-sparing effect. Normally, the process of potassium excretion is driven by the electrochemical gradient produced by sodium reabsorption. As sodium is reabsorbed, it leaves a negative potential in the lumen, while producing a positive potential in the principal cell. This potential promotes potassium excretion through apical potassium channels. By inhibiting sodium reabsorption, triamterene also inhibits potassium excretion.Triamterene is used for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema, and edema due to secondary hyperaldosteronism. Triamterene is maeketed under the trade name Dyrenium.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
5.0 µM [IC50] | |||
Target ID: CHEMBL2111408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/6321204 |
127.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DYRENIUM Approved UseEdema: For the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; also in steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Launch Date1964 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
46.4 ng/mL |
37.5 mg 1 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
125.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166735 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
44.77 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21193005 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
148.7 ng × h/mL |
37.5 mg 1 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
488.4 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166735 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
190.69 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21193005 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/21193005 |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2 h |
unknown |
TRIAMTERENE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
33% |
37.5 mg 1 times / day multiple, oral dose: 37.5 mg route of administration: Oral experiment type: MULTIPLE co-administered: HYDROCHLOROTHIAZIDE |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
38.7% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7166735 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
TRIAMTERENE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 2 times / day multiple, oral Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Co-administed with:: hydrochlorothiazide(50 mg twice daily; 28 days) Sources: |
unhealthy, 54 ± 3 years n = 9 Health Status: unhealthy Condition: hypokalemia Age Group: 54 ± 3 years Population Size: 9 Sources: |
Other AEs: Kidney failure... |
37.5 mg 1 times / day single, oral Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Co-administed with:: hydrochlorothiazide(25 mg) Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Hyperkalemia... AEs leading to discontinuation/dose reduction: Hyperkalemia Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Kidney failure | acute | 100 mg 2 times / day multiple, oral Dose: 100 mg, 2 times / day Route: oral Route: multiple Dose: 100 mg, 2 times / day Co-administed with:: hydrochlorothiazide(50 mg twice daily; 28 days) Sources: |
unhealthy, 54 ± 3 years n = 9 Health Status: unhealthy Condition: hypokalemia Age Group: 54 ± 3 years Population Size: 9 Sources: |
Hyperkalemia | Disc. AE | 37.5 mg 1 times / day single, oral Dose: 37.5 mg, 1 times / day Route: oral Route: single Dose: 37.5 mg, 1 times / day Co-administed with:: hydrochlorothiazide(25 mg) Sources: |
unhealthy Health Status: unhealthy Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://dmd.aspetjournals.org/content/36/6/995 Page: 3.0 |
yes | |||
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Irreversible renal failure associated with triamterene. | 1991 |
|
Folic acid antagonists during pregnancy and risk of birth defects. | 2001 Mar 22 |
|
Neural tube defects in relation to use of folic acid antagonists during pregnancy. | 2001 May 15 |
|
In vitro antioxidant and photo-oxidant properties of dipyridamole. | 2001 Nov-Dec |
|
Prolonged exercise following diuretic-induced hypohydration effects on fluid and electrolyte hormones. | 2001 Sep |
|
Determination of hydrochlorothiazide, triamterene and propranolol hydrochloride by the spectrophotometric method and high-performance liquid chromatography (HPLC). | 2001 Sep-Oct |
|
Effects of anion and cation inhibitors and carbonic anhydrase inhibitors upon the activity of the gypsy moth (Lepidoptera: Lymantriidae) nucleo-polyhedrovirus. | 2002 Apr |
|
Use of the trispan device to assist coil embolization of high-flow arteriovenous fistulas. | 2002 Aug |
|
Screening for 18 diuretics and probenecid in doping analysis by liquid chromatography-tandem mass spectrometry. | 2002 Dec |
|
Non-traumatic neurological emergencies: emergency neuroradiological interventions. | 2002 Jul |
|
[Liddle's syndrome: late diagnosis of a rare cause of arterial hypertension]. | 2002 May-Jun |
|
Direct determination of triamterene by potentiometry using a coated wire selective electrode. | 2003 Dec 4 |
|
Drug-induced myopia. | 2003 Feb |
|
Pharmacological characterization of unique prazosin-binding sites in human kidney. | 2003 Jul |
|
Photostability studies on the furosemide-triamterene drug association. | 2003 Sep |
|
Treatment of congenital nephrogenic diabetes insipidus with hydrochlorothiazide and amiloride in an adult patient. | 2004 |
|
[Determination of five components in compound hypotensive tablet by HPLC]. | 2004 Aug |
|
Application of PLS regression to fluorimetric data for the determination of furosemide and triamterene in pharmaceutical preparations and triamterene in urine. | 2004 Feb 6 |
|
Application of a fluorescence sensor for miniscale on-line monitoring of powder mixing kinetics. | 2004 Jan |
|
[Circadian rhythm of the renin-angiotensin-aldosterone system: a summary of our research studies]. | 2004 Jul-Aug |
|
Triamterene-beta-cyclodextrin systems: preparation, characterization and in vivo evaluation. | 2004 Mar 29 |
|
Attenuation of the kaluretic properties of furosemide by triamterene (Dyrenium) in healthy volunteers. | 2005 Feb |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction. | 2005 Sep |
|
[Drug-induced renal calculi]. | 2006 Apr |
|
[Liddle syndrome: Pathogenesis, pathophysiology, and therapy]. | 2006 Feb |
|
Periprocedural morbidity and mortality by endovascular treatment of cerebral aneurysms with GDC: a retrospective 12-year experience of a single center. | 2007 Apr |
|
Naturalised Vitis rootstocks in Europe and consequences to native wild grapevine. | 2007 Jun 13 |
|
A study of western pharmaceuticals contained within samples of Chinese herbal/patent medicines collected from New York City's Chinatown. | 2007 Sep |
|
Determination of norfloxacin in rat liver perfusate using capillary electrophoresis with laser-induced fluorescence detection. | 2007 Sep 1 |
|
Practical aspects in the management of hypokalemic periodic paralysis. | 2008 Apr 21 |
|
Development of a vessel-simulating flow-through cell method for the in vitro evaluation of release and distribution from drug-eluting stents. | 2008 Aug 25 |
|
Chemical and genetic validation of dihydrofolate reductase-thymidylate synthase as a drug target in African trypanosomes. | 2008 Jul |
|
Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. | 2008 Jun |
|
Drug-induced crystal nephropathy: an update. | 2008 Mar |
|
Responses to diuretic treatment in gene-targeted mice lacking serum- and glucocorticoid-inducible kinase 1. | 2009 |
|
Graz Endocrine Causes of Hypertension (GECOH) study: a diagnostic accuracy study of aldosterone to active renin ratio in screening for primary aldosteronism. | 2009 Apr 7 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/ppa/triamterene.html
Edema: Oral: 100 to 300 mg daily in 1 to 2 divided doses; maximum dose: 300 mg daily
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6129855
Triamterene in the concentration range from 8X10(-13) mol/l to 8X10(-3) mol/l exerted a dose-dependent inhibitory effect of the rat kidney plasma membrane Na-K-Mg-ATPase and Na-K-ATPase activities--estimated IC50 values lay at about 8X10(-3) mol/l and 8X10(-7) mol/l, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C03DB02
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
||
|
NDF-RT |
N0000175418
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
||
|
NCI_THESAURUS |
C49186
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
||
|
LIVERTOX |
NBK547859
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
||
|
NDF-RT |
N0000175359
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
||
|
WHO-VATC |
QC03DB02
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
||
|
NDF-RT |
N0000008859
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
77625
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
1680007
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL585
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
396-01-0
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
5546
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
DB00384
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
Triamterene
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
100000092570
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
TRIAMTERENE
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
C29519
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
10763
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | RxNorm | ||
|
639359
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
3405
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
SUB11256MIG
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
2728
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
DTXSID6021373
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
D014223
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
m11030
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
4329
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
1266
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
206-904-3
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
WS821Z52LQ
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
9671
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY | |||
|
WS821Z52LQ
Created by
admin on Sat Dec 16 04:48:13 GMT 2023 , Edited by admin on Sat Dec 16 04:48:13 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE ACTIVE (PARENT)
METABOLITE ACTIVE (PARENT)